aap Implantate AG / Key word(s): Contract/Agreement
23.03.2012 12:07
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
aap Biomaterials GmbH, a subsidiary of aap Implantate AG, a medical
technology company listed in the Frankfurt Stock Exchange's Prime Standard
segment, today signed an exclusive license agreement with a world-leading
medical technology company. aap has granted an exclusive license to an
IP-protected product of its biomaterial portfolio and remains at the same
time the product's manufacturer. The exclusive license relates to all
product indications, excluding Dental, oral care and food additives and is
valid worldwide except in the United States.
With the signing, aap will receive a one-time license fee of approx. EUR
2.1 million.
Contact:
aap Implantate AG; Marc Heydrich; Investor Relations; Lorenzweg 5; D-12099
Berlin
Tel.: ++49/30/750 19 - 134; Fax.: ++49/30/750 19 - 290; m.heydrich@aap.de
23.03.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Germany
Phone: +49 (0) 30 75 01 90
Fax: +49 (0) 30 75 01 91 11
E-mail: info@aap.de
Internet: www.aap.de
ISIN: DE0005066609
WKN: 506660
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: aap signs exclusive license agreement for an IP-protected product of its biomaterial portfolio
| Source: EQS Group AG